YURAK YETISHMOVCHILIGI VA YANGI DAVOLASH STRATEGIYALARI.
Keywords:
Yurak yetishmovchiligi, SGLT2 inhibitörlari, regenerativ terapiya, baroreseptor stimulyatsiyasi, sun’iy yurak, kardiomiopatiya, ejection fraction, kardiologiya, zamonaviy davolash.Abstract
Ushbu maqolada yurak yetishmovchiligi (YY) patofiziologiyasi, tarqalish darajasi va zamonaviy davolash strategiyalari tahlil qilinadi. XX asr oxirlaridan buyon yurak yetishmovchiligi yurak-qon tomir tizimi kasalliklari orasida o‘lim va nogironlikning asosiy sababi bo‘lib qolmoqda. Traditsion medikamentoz terapiyaga parallel ravishda, so‘nggi yillarda kardiologiyada yangi usullar – SGLT2 inhibitörlari, baroreseptor stimulyatsiyasi, regenerativ terapiya va sun’iy yurak qurilmalari joriy etilmoqda. Maqolada ushbu usullarning klinik samaradorligi, qo‘llash cheklovlari va istiqbollari tahlil qilinadi.
References
1. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. doi:10.1056/NEJMoa1911303
2. Packer, M., Anker, S.D., Butler, J., et al. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15), 1413–1424. doi:10.1056/NEJMoa2022190
3. Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200. doi:10.1093/eurheartj/ehw128
4. Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O. (2020). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (11th ed.). Philadelphia: Elsevier.
5. Zile, M.R., Brutsaert, D.L. (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part II. Circulation, 105(12), 1503–1508. doi:10.1161/hc1202.105289
6. Abraham, W.T., Lindenfeld, J., Raval, N., et al. (2019). Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 73(23), 2850–2860. doi:10.1016/j.jacc.2019.03.502
7. Bartunek, J., Behfar, A., Dolatabadi, D., et al. (2017). Cardiopoietic stem cell therapy in heart failure. Journal of the American College of Cardiology, 70(5), 725–737. doi:10.1016/j.jacc.2017.06.010
8. Slaughter, M.S., Rogers, J.G. (2014). Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation, 129(8), 923–935. doi:10.1161/CIRCULATIONAHA.113.001012
9. National Heart, Lung, and Blood Institute. (2023). Heart Failure. https://www.nhlbi.nih.gov/health-topics/heart-failure
10. FDA. (2024). Drugs@FDA Database. https://www.accessdata.fda.gov/scripts/cder/daf/
